9 Meters Biopharma, Inc. (NMTR): Price and Financial Metrics
GET POWR RATINGS... FREE!
NMTR Stock Price Chart Interactive Chart >
NMTR Price/Volume Stats
| Current price | $2.02 | 52-week high | $15.74 |
| Prev. close | $1.99 | 52-week low | $1.00 |
| Day low | $1.96 | Volume | 54,608 |
| Day high | $2.09 | Avg. volume | 165,890 |
| 50-day MA | $1.74 | Dividend yield | N/A |
| 200-day MA | $4.93 | Market Cap | 26.17M |
9 Meters Biopharma, Inc. (NMTR) Company Bio
9 Meters Biopharma, Inc. operates as a biotechnological company. The Company focuses on development of drugs and treatments for rare disorders and unmet needs. 9 Meters Biopharma serves customers worldwide.
Latest NMTR News From Around the Web
Below are the latest news stories about 9 METERS BIOPHARMA INC that investors may wish to consider to help them evaluate NMTR as an investment opportunity.
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome (SBS). The study design follows the Company's successful End-of-Phase 2 meeting and incorporates input received from the U.S. |
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced a continuing collaboration agreement with Gustave Roussy, a world-renowned cancer center in France, using 9 Meters' small molecule tight junction microbiome modulator NM-102. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into the systemic circulation. |
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), 9 Meters Biopharma (NMTR) and Graphite Bio (GRPH)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN – Research Report), 9 Meters Biopharma (NMTR – Research Report) and Graphite Bio (GRPH – Research Report). BioMarin Pharmaceutical (BMRN) In a report issued on November 8, Andreas Argyrides from Wedbush maintained a Hold rating on BioMarin Pharmaceutical, with a price target of $74.00. The company's shares closed last Thursday at $83.83. According to TipRanks. |
Maxim Group Remains a Hold on 9 Meters Biopharma (NMTR)In a report released yesterday, Naz Rahman from Maxim Group maintained a Hold rating on 9 Meters Biopharma (NMTR - Research Report). The company's shares opened today at $2.15.According to TipRanks, Rahman is an analyst with an average return of -38.3% and a 16.88% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Clene.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 9 Meters Biopharma with a $4.00 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $24.00 and a one-year low of $2.11. |
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 20229 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended September 30, 2022. |
NMTR Price Returns
| 1-mo | 60.32% |
| 3-mo | -14.77% |
| 6-mo | -61.27% |
| 1-year | -86.77% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 60.32% |
| 2022 | -93.56% |
| 2021 | 13.93% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...